Michele C. Azada

1.4k total citations · 1 hit paper
13 papers, 1.1k citations indexed

About

Michele C. Azada is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Michele C. Azada has authored 13 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Michele C. Azada's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (9 papers) and Cancer therapeutics and mechanisms (6 papers). Michele C. Azada is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (9 papers) and Cancer therapeutics and mechanisms (6 papers). Michele C. Azada collaborates with scholars based in United States. Michele C. Azada's co-authors include Sai‐Hong Ignatius Ou, Siraj M. Ali, Vincent A. Miller, Samuel J. Klempner, Alberto Chiappori, Tomohiro Tanaka, Frédéric Boisserie, Leena Gandhi, Howard West and Gregory J. Riely and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Michele C. Azada

13 papers receiving 1.1k citations

Hit Papers

Safety and activity of alectinib against systemic disease... 2014 2026 2018 2022 2014 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
    2014 538 citations Shirish M. Gadgeel, Leena Gandhi et al. The Lancet Oncology profile →

Peers

Michele C. Azada
Gaëlle Klingelschmitt Switzerland
Lisa Cupit United States
Robin Wiltshire United States
Anna Maria Calella Italy
L. Véronèse Switzerland
Anna Wrona Poland
Edna Chow‐Maneval United States
Vanessa Giannone United States
Wee-Lee Yeo Singapore
G. Jeannin France
Gaëlle Klingelschmitt Switzerland
Michele C. Azada
Citations per year, relative to Michele C. Azada Michele C. Azada (= 1×) peers Gaëlle Klingelschmitt

Countries citing papers authored by Michele C. Azada

Since Specialization
Citations

This map shows the geographic impact of Michele C. Azada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele C. Azada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele C. Azada more than expected).

Fields of papers citing papers by Michele C. Azada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele C. Azada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele C. Azada. The network helps show where Michele C. Azada may publish in the future.

Co-authorship network of co-authors of Michele C. Azada

This figure shows the co-authorship network connecting the top 25 collaborators of Michele C. Azada. A scholar is included among the top collaborators of Michele C. Azada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele C. Azada. Michele C. Azada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Ou, Sai‐Hong Ignatius, et al.. (2016). Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation. Lung Cancer. 96. 15–18. 19 indexed citations
2.
Ou, Sai‐Hong Ignatius, Joel Greenbowe, Ziad U. Khan, et al.. (2015). I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung Cancer. 88(2). 231–234. 61 indexed citations
3.
4.
Ou, Sai‐Hong Ignatius, Zachary R. Chalmers, Michele C. Azada, et al.. (2015). Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling. Lung Cancer. 88(3). 352–354. 29 indexed citations
5.
6.
Ou, Sai‐Hong Ignatius, Jeffrey C. Milliken, Michele C. Azada, et al.. (2015). ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. Lung Cancer. 91. 70–72. 40 indexed citations
7.
8.
Lu, Stephanie, Michele C. Azada, & Sai‐Hong Ignatius Ou. (2014). Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient. Lung Cancer. 87(2). 207–209. 19 indexed citations
9.
Gadgeel, Shirish M., Leena Gandhi, Gregory J. Riely, et al.. (2014). Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. The Lancet Oncology. 15(10). 1119–1128. 538 indexed citations breakdown →
10.
Ou, Sai‐Hong Ignatius, Samuel J. Klempner, Joel Greenbowe, et al.. (2014). Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib. Journal of Thoracic Oncology. 9(12). 1821–1825. 70 indexed citations
11.
Ou, Sai‐Hong Ignatius, et al.. (2013). Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer. 119(11). 1969–1975. 54 indexed citations
12.
13.
Ou, Sai‐Hong Ignatius, et al.. (2011). Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib. Journal of Thoracic Oncology. 6(12). 2135–2137. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gaëlle Klingelschmitt Breakdown of academic impact, for papers by Lisa Cupit Breakdown of academic impact, for papers by Robin Wiltshire Breakdown of academic impact, for papers by Anna Maria Calella Breakdown of academic impact, for papers by L. Véronèse Breakdown of academic impact, for papers by Anna Wrona Breakdown of academic impact, for papers by Edna Chow‐Maneval Breakdown of academic impact, for papers by Vanessa Giannone Breakdown of academic impact, for papers by Wee-Lee Yeo Breakdown of academic impact, for papers by G. Jeannin
Rankless by CCL
2026